A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer

摘要: The immunohistochemical determination of HER-2 to identify patients with advanced breast cancer candidates for Trastuzumab treatment proved neither accurate nor fully reliable, possibly because none the current reagents detects specific antigenic site target Trastuzumab. To circumvent this problem, we conjugated NH2 groups biotin, and compound obtained, designated BiotHER, was added directly tissue sections. Biotin-labelling revealed horseradish peroxidase-conjugated streptavidin. Specificity sensitivity BiotHER immunostaining respect amplification were tested on 164 carcinoma samples. staining detected tumour cell membrane 12% all specimens in 49% gene amplification, while absent nonamplified tumours. Predictivity status clinical outcome analysed 54 amplified treated plus chemotherapy. staining, 50% tumours an independent predictor outcome. In fact, positivity independently associated increased likelihood response reduced risk progression death. Biotinylated can thus be used detection overexpression cancer, has potential likely benefit from treatment.